We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Optimized Pooled Testing Approach Could Transform Public Health Screening for Infectious Diseases

By LabMedica International staff writers
Posted on 13 Dec 2024
Print article
Image: The new study highlights efficiency in detecting infectious diseases (Photo courtesy of Adobe Stock)
Image: The new study highlights efficiency in detecting infectious diseases (Photo courtesy of Adobe Stock)

Traditional individual testing methods can be resource-intensive, particularly when it comes to large-scale screenings. Pooled testing, on the other hand, enables the testing of multiple specimens together, which reduces both cost and time. This approach has been particularly useful in situations where disease prevalence is low, such as during early screenings or when monitoring for diseases like HIV and chlamydia. In an effort to accelerate and make large-scale disease testing more affordable, researchers have now created an optimized method for pooled testing, which has the potential to revolutionize public health screening for infectious diseases.

A study conducted by researchers at the University of Louisiana at Lafayette (Lafayette, LA, USA) examined the benefits of using pooled testing for detecting infectious diseases, particularly in cases of low prevalence. The team developed a framework to determine the most effective pool size for different infectious diseases, balancing both cost and testing efficiency. Their research utilized data on diseases like HIV, gonorrhea, chlamydia, and SARS-CoV-2.

The researchers found that by strategically pooling specimens, testing costs could be significantly reduced without sacrificing accuracy—an important discovery as health systems face increasing demand for screening across various diseases, including HIV, gonorrhea, and COVID-19. Their findings, published in the Journal of Agricultural, Biological, and Environmental Statistics, revealed that by adjusting pool sizes according to specific infection prevalence rates, public health agencies could realize considerable cost savings while still ensuring accurate prevalence estimates. The software tools developed in this study are now available for download, providing valuable resources for public health officials and researchers worldwide.

“Our findings suggest that careful design and optimization of pooled testing can yield substantial benefits for disease surveillance efforts, particularly in resource-limited settings,” said Dr. Md S. Warasi, Assistant Professor of Mathematics and Statistics at Radford University. “The study provides a new software package and a user-friendly software application to aid health departments and researchers in implementing these optimized testing protocols.”

“The ability to efficiently detect and monitor infectious diseases is crucial for timely interventions. By refining how pooled testing is conducted, we hope to empower health departments worldwide to improve their screening processes and respond faster to potential outbreaks,” added Dr. Kumer P. Das, Assistant Vice President for Research and Innovation at theUniversity of Louisiana at Lafayette.

 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.